Currently out of the existing stock ratings of Andrew Tsai, 64 are a BUY (94.12%), 4 are a HOLD (5.88%).

Andrew Tsai

Work Performance Price Targets & Ratings Chart

Analyst Andrew Tsai, currently employed at JEFFERIES, carries an average stock price target met ratio of 49.22% that have a potential upside of 45.65% achieved within 184 days.

Andrew Tsai’s has documented 131 price targets and ratings displayed on 19 stocks. The coverage is on Healthcare, Technology sectors.

Most recent stock forecast was given on ATAI, ATAI Life Sciences BV at 17-Jul-2026.

Wall Street Analyst Andrew Tsai

Analyst best performing recommendations are on XENE (XENON PHARMACEUTICALS).
The best stock recommendation documented was for XENE (XENON PHARMACEUTICALS) at 8/30/2021. The price target of $28 was fulfilled within 35 days with a profit of $11.09 (65.58%) receiving and performance score of 18.74.

Average potential price target upside

of $79.58 (66.91%) on AXSM (AXSOME THERAPEUTICS).
of $52.87 (18.79%) on VRTX (VERTEX PHARMACEUTICALS).
of $27.75 (64.04%) on ITCI (INTRACELLULAR TH).

ATHA Athira Pharma ITCI Intracellular Th XENE Xenon Pharmaceuticals ATAI ATAI Life Sciences BV SAGE Sage Therapeutic VTGN VistaGen Therapeutics MRNS Marinus Pharmaceuticals RLMD Relmada Therapeutics RCKT Rocket Pharmaceuticals SRPT Sarepta Therapeutics VIGL Vigil Neuroscience BBIO BridgeBio Pharma LXRX Lexicon Pharmaceuticals AXSM Axsome Therapeutics VRTX Vertex Pharmaceuticals ANRO Alto Neuroscience IT Gartner PNT POINT Biopharma Global SUPN Supernus Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Graig Suvannavejh (MIZUHO)